Zenbexus FDA label names Hematogenix NGF in MRD efficacy evidence
Summary
FDA granted accelerated approval to the specified iberdomide combination on 13 August 2026.
Source Date
August 13, 2026
Source checked
October 5, 2026
Event Type
approval
Event Date
August 13, 2026
Geography
US
Commercial Regulatory Status
Accelerated drug approval; assay clearance or approval not established
Related CFCM Topics
/resources /market-intelligence
Category
Regulatory
Primary source
Read the source →Facts supported by cited sources
FDA granted accelerated approval to the specified iberdomide combination on 13 August 2026.
Label Table 4 reports MRD-negative complete response in 85/207 (41%) versus 44/213 (21%), p<0.0001.
The Table 4 footnote identifies a Hematogenix NGF assay at a 10^-5 threshold.
Claims Requiring Caution
Drug approval is not assay approval or clearance.
The threshold is not a complete analytical validation dossier; these trial results do not establish interchangeability with other MRD assays.
Why It Matters
CFCM explainer
Trial endpoint → assay review → product label. Separate question → assay authorization.
CFCM schematic based on the cited regulatory documents. Alt text: distinction between trial assay review and assay authorization.
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →